A review of clinical and molecular prognostic factors in osteosarcoma
Open accessThe DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
A System for the Surgical Staging of Musculoskeletal Sarcoma
ENNEKING, W. F., SPANIER, S. S., & GOODMAN, M. A. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198011000-00013 · Cited by 2,500
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 8×
“Clinical factors predictive of primary metastases include axial tumours, large tumours and a long history of symptoms (Bielack et al. 2002).”
BackgroundResultInfluentialAJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,410
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Taichman, R. S., Cooper, C. R., Keller, E. T., Pienta, K. J., Taichman, N. S., & McCauley, L. K. (2002) · PubMed · Cited by 1,118
Folkman, J., & Haudenschild, C. (1980) · Nature · doi:10.1038/288551a0 · Cited by 1,037 · cited 1×
“This research Weld, pioneered by Judah Folkman (1982; Folkman and Haudenschild 1980), has contributed signiWcantly to the molecular revolution in cancer research.”
MethodA system for the surgical staging of musculoskeletal sarcoma.
Enneking, W. F., Spanier, S. S., & Goodman, M. A. (1981) · PubMed · Cited by 1,001
Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D. B., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00597-9 · Cited by 728 · cited 14×
“Contrary to this, Mantadakis et al. (2001), found no relationship between MVD and long-term survival, and a further study found no correlation between VEGF expression or MVD and survival (Ek et al. 2006b).”
InfluentialCXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer
Smith, M. C. P., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., Piwnica-Worms, D., & Luker, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1844 · Cited by 715 · cited 1×
“The CXRR4/SDF-1 system has been found to correlate signiWcantly with the presence of metastases in a number of tumours including prostate, melanoma, breast, and rhabdomyosarcoma (Libura et al. 2002; Murakami et al. 2002; Smith et al. 2004; Taichman et al. 2002).”
BackgroundThe membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M., & Helman, L. J. (2004) · Nature Medicine · doi:10.1038/nm982 · Cited by 705 · cited 3×
“Increased ezrin expression in paediatric osteosarcoma patients is associated with reduced diseasefree intervals, and down regulation of ezrin expression in a mouse model of human osteosarcoma, is associated with pulmonary metastasis inhibition (Khanna et al. 2004).”
BackgroundInfluentialBacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P. (2006) · Cancer · doi:10.1002/cncr.21724 · Cited by 569 · cited 7×
“associated with a worse prognosis on multivariate analysis (Bacci et al. 2006) while a further study has showed that a volume greater than 400 cm(3) has a statistically worse prognosis (Lindner et al.”
BackgroundMethodInfluentialRougraff, B. T., Simon, M. A., Kneisl, J. S., Greenberg, D. B., & Mankin, H. J. (1994) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-199405000-00004 · Cited by 536 · cited 1×
“Functionally superior, limb-sparing surgery (Davis et al. 1999) has been cemented as the default management pathway based on a number of studies (RougraV et al. 1994; Simon et al. 1986; Sluga et al. 1999; Szendroi et al. 2000) which have all reported no diVerence in overall survival between…”
BackgroundTakahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K., Kitaura, Y., Takai, S., Sasahara, R. M., Horimoto, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13221 · Cited by 492 · cited 1×
“RECK is a newly discovered membrane-bound protein which was Wrst identiWed by Takahashi et al. (1998) by screening a Wbroblast cDNA library for genes inducing reversion to a Xattened morphology in a Ki-ras transformed Wbrosarcoma cell line.”
BackgroundLimb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur.
Simon, M. A., Aschliman, M. A., Thomas, N., & Mankin, H. J. (1986) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-198668090-00005 · Cited by 469
Limb-Salvage Treatment Versus Amputation for Osteosarcoma of the Distal End of the Femur
Simon, M. A., Aschliman, M. A., Thomas, N., & Mankin, H. J. (2005) · The Journal of Bone & Joint Surgery · doi:10.2106/jbjs.8712.cl · Cited by 452 · cited 2×
“…limb-sparing surgery (Davis et al. 1999) has been cemented as the default management pathway based on a number of studies (RougraV et al. 1994; Simon et al. 1986; Sluga et al. 1999; Szendroi et al. 2000) which have all reported no diVerence in overall survival between amputation and…”
BackgroundMethodPrognostic factors in osteosarcoma: a critical review.
Davis, A. M., Bell, R. S., & Goodwin, P. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.423 · Cited by 424 · cited 3×
“Tumour response to chemotherapy A critical appraisal (Davis et al. 1994) of eight papers concerned with prognostic factors in osteosarcoma, concluded that percentage necrosis of the tumour in response to preoperative chemotherapy was the most signiWcant factor correlating with disease free survival.”
BackgroundExpression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332103 · Cited by 399 · cited 2×
“levels of expressed P-gp in osteosarcoma is associated with a signiWcant reduction in the probability of remaining event-free after diagnosis but does not correlate with the level of post-chemotherapy tumour necrosis (Baldini et al. 1995; Chan et al. 1997).”
BackgroundMurakami, T., Maki, W. C., Cardones, A. R., Fang, H., Tun-Kyi, A., Nestle, F. O., & Hwang, S. T. (2002) · PubMed · Cited by 396
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345 · cited 2×
“while in previous studies on relative values (Bacci et al. 1990; Bieling et al. 1991; Winkler et al. 1984), multivariate analysis was either not performed or not signiWcant.”
MethodResultOsteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
Ozaki, T., Flege, S., Kevric, M., Lindner, N., Maas, R., Delling, G., Schwarz, R., von Hochstetter, A. R., Salzer-Kuntschik, M., Berdel, W. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.142 · Cited by 342
Endogenous angiogenesis inhibitors
FOLKMAN, J. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321 · cited 2×
“There is a concerted eVort to utilise anti- angiogenic agents, such as Avastin and Endostatin, which work to inhibit the VEGF signalling pathway (Folkman 2004; Tjin Tham Sjin et al. 2006).”
MethodThe New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308 · cited 1×
“In the last few decades it has become more evident that the way forward in osteosarcoma management, and cancer in general, will be through a focused inter-relation of clinical and molecular information (Papachristou and Papavassiliou 2007; Varmus 2006).”
BackgroundLibura, J., Drukala, J., Majka, M., Tomescu, O., Navenot, J. M., Kucia, M., Marquez, L., Peiper, S. C., Barr, F. G., Janowska-Wieczorek, A., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0031 · Cited by 306 · cited 3×
“…released from endothelium in target tissues (i.e., lung and bone) bind to their receptors on tumour cells in the primary lesion and result in both the release of MMPs (Paoletti et al. 2001) and a chemoattractant gradient (Libura et al. 2002), leading to metastasis to the speciWc target tissue.”
Background(2000) · PubMed · Cited by 304
Picci, P., Sangiorgi, L., Rougraff, B. T., Neff, J. R., Casadei, R., & Campanacci, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2699 · Cited by 300 · cited 1×
“Another study had very similar Wndings in that none of those undergoing amputation had LR, whereas 10% of those with limb-sparing surgery had LR (Picci et al. 1994).”
ResultOsteosarcoma of the spine: Experience of the Cooperative Osteosarcoma Study Group
Ozaki, T., Flege, S., Liljenqvist, U., Hillmann, A., Delling, G., Salzer‐Kuntschik, M., Jürgens, H., Kotz, R., Winkelmann, W., & Bielack, S. S. (2002) · Cancer · doi:10.1002/cncr.10258 · Cited by 283 · cited 1×
“Studies have reported median survival times of 10–23 months (Shives et al. 1986; Ozaki et al. 2002).”
BackgroundTumor size and prognosis in aggressively treated osteosarcoma.
Bieling, P., Rehan, N., Winkler, P., Helmke, K., Maas, R., Fuchs, N., Bielack, S., Heise, U., Jurgens, H., Treuner, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.848 · Cited by 275 · cited 4×
“…absolute tumour volume, stage and site of the tumour remain the most useful because in general they have clear cut-oV points identiWed in the literature between good and bad outcomes, for example age greater than 40 (Aksnes et al. 2006), and tumour volume greater than 150 cm3 (Bieling et al. 1996).”
BackgroundInfluentialPicci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., Bertoni, F., Guerra, A., Capanna, R., Albisinni, U., et al. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7<1515::aid-cncr2820560707>3.0.co;2-6 · Cited by 274 · cited 1×
“The most predictive cut oV point for favourable or unfavourable response to chemotherapy is greater than 90% or less than 90% necrosis, respectively (Picci et al. 1985).”
BackgroundANGIOGENESIS: INITIATION AND CONTROL*
Folkman, J. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb25720.x · Cited by 262
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260 · cited 2×
“…inactivation of the key tumour-suppressor gene p53 and its protein product plays a prominent role in the development of most tumours, typically through the loss of cell cycle arrest and repair mechanism, and also more recently discovered, a loss of anti-angiogenesis (Teodoro et al. 2007).”
BackgroundMutation spectrum of the retinoblastoma gene in osteosarcomas.
Wadayama, B., Toguchida, J., Shimizu, T., Ishizaki, K., Sasaki, M. S., Kotoura, Y., & Yamamuro, T. (1994) · PubMed · Cited by 250
PEDF: anti-angiogenic guardian of ocular function
Bouck, N. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02362-6 · Cited by 235 · cited 1×
“Pigment epithelium derived factor (PEDF) is a protein initially identiWed by its absence in angiogenic eye disorders, where under normal conditions it has a protective role against excessive angiogenesis (Bouck 2002; Holekamp et al. 2002).”
BackgroundHolekamp, N. M., Bouck, N., & Volpert, O. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01549-0 · Cited by 229 · cited 1×
“Pigment epithelium derived factor (PEDF) is a protein initially identiWed by its absence in angiogenic eye disorders, where under normal conditions it has a protective role against excessive angiogenesis (Bouck 2002; Holekamp et al. 2002).”
BackgroundEzrin, a key component in tumor metastasis
Hunter, K. W. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.03.001 · Cited by 229 · cited 2×
“Ezrin The ezrin protein has a role in cell–cell interactions, signal transduction, linkage between actin Wlaments and the cell membrane, and when upregulated it drives metastasis (Hunter 2004).”
BackgroundNemunaitis, J. J., Poole, C. J., Primrose, J. M., Rosemurgy, A. S., Malfetano, J. H., Brown, P. D. N., de González, A. B., Cornish, A. G., Lynch, K., Rasmussen, H. S., et al. (1998) · PubMed · Cited by 224
Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of Osteosarcoma
Wan, X., Mendoza, A., Khanna, C., & Helman, L. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3135 · Cited by 216 · cited 1×
“Rapamycin has been found to inhibit ezrin-mediated pathways leading to reduced lung metastases, again in a mouse model of osteosarcoma (Wan et al. 2005).”
BackgroundSurgical outcomes in osteosarcoma
Grimer, R. J., Taminiau, A. M., & Cannon, S. R. (2002) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.84b3.0840395 · Cited by 216
ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
Onda, M., Matsuda, S., Higaki, S., Iijima, T., Fukushima, J.-I., Yokokura, A., Kojima, T., Horiuchi, H., Kurokawa, T., & Yamamoto, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1<71::aid-cncr13>3.0.co;2-5 · Cited by 201 · cited 1×
“Onda et al. (1996) found no evidence of mutation or ampliWcation of the c-erbB-2 gene amongst 26 diVerent osteosarcoma tissues.”
BackgroundGermline mutations of the p53 tumor suppressor gene in children with osteosarcoma.
McIntyre, J. F., Smith-Sorensen, B., Friend, S. H., Kassell, J., Borresen, A. L., Yan, Y. X., Russo, C., Sato, J., Barbier, N., & Miser, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.925 · Cited by 200 · cited 2×
“small proportion of osteosarcomas are associated with either germ-line p53 mutations or the Li-Fraumeni syndrome (McIntyre et al. 1994).”
BackgroundLoss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.
Feugeas, O., Guriec, N., Babin-Boilletot, A., Marcellin, L., Simon, P., Babin, S., Thyss, A., Hofman, P., Terrier, P., Kalifa, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.467 · Cited by 199 · cited 1×
“Similar Wndings have been reported in other studies (Benassi et al. 1999; Feugeas et al. 1996) which are summarised in Table 2.”
ResultHauben, E. I., Weeden, S., Pringle, J., Van Marck, E. A., & Hogendoorn, P. C. W. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00037-0 · Cited by 191 · cited 3×
“The same applies to assessment of percentage necrosis in tumours post-chemotherapy, where as previously discussed only by analysing a whole cross-section of tumour will an accurate result be attained (Hauben et al. 2002).”
BackgroundInfluentialDavis, A. M., Devlin, M., Griffin, A. M., Wunder, J. S., & Bell, R. S. (1999) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(99)90161-2 · Cited by 191 · cited 2×
“Functionally superior, limb-sparing surgery (Davis et al. 1999) has been cemented as the default management pathway based on a number of studies (RougraV et al. 1994; Simon et al. 1986; Sluga et al. 1999; Szendroi et al. 2000) which have all reported no diVerence in overall survival between…”
BackgroundAlterations of thep53, Rb andMDM2 genes in osteosarcoms
Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koefflar, H. P. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213553 · Cited by 190
Pathologic Fracture in Osteosarcoma: Prognostic Importance and Treatment Implications
Scully, S. P., Ghert, M. A., Zurakowski, D., Thompson, R. C., & Gebhardt, M. C. (2002) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200201000-00008 · Cited by 187 · cited 4×
“Similarly, other results (Abudu et al. 1996; Scully et al. 2002) revealed no signiWcant diVerence in survival between the two options, although Abudu et al. found that a signiWcant increase in local recurrence occurred in the instance of limb sparing surgery.”
ResultInfluentialC-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression
Gamberi, G., Benassi, M. S., Bohling, T., Ragazzini, P., Molendini, L., Sollazzo, M. R., Pompetti, F., Merli, M., Magagnoli, G., Balladelli, A., et al. (1998) · Oncology · doi:10.1159/000011912 · Cited by 179 · cited 1×
“In osteosarcoma elevated c-Fos levels correspond with higher grades of tumour (Franchi et al. 1998; Wu et al. 1990) and also the propensity to develop metastases (Gamberi et al. 1998).”
BackgroundUrokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong, P., & Nadesapillai, A. P. W. (2003) · PubMed · doi:10.1097/01.blo.0000093845.72468.bd · Cited by 167 · cited 2×
“The main pathway in this system involves a ligand (uPA) binding to its receptor (uPAR), which subsequently results in uPA becoming active, result- ing in cleavage of plasminogen to plasmin (Choong and Nadesapillai 2003).”
BackgroundSelf-citationLong-Term Results After Repeated Surgical Removal of Pulmonary Metastases
Kandioler, D., Krömer, E., Tüchler, H., End, A., Müller, M. R., Wolner, E., & Eckersberger, F. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(98)00019-8 · Cited by 164 · cited 1×
“After two or more metastasectomies one study population maintained reasonable survival Wgures of 48% at 5 years (Kandioler et al. 1998).”
BackgroundUrokinase receptor and colorectal cancer survival
GANESH, S. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91427-3 · Cited by 161 · cited 1×
“The uPA/uPAR system is upregulated in many common tumours, and speciWcally in colorectal (Ganesh et al. 1994), ovarian (Kuhn et al. 1994), renal (Hofmann et al. 1996) and prostate cancer (McCabe et al. 2000), there is evidence linking an upregulated uPA system with poor survival.”
BackgroundParry, M., Laitinen, M., Albergo, J. I., Jeys, L. M., Carter, S. R., Gaston, C. L., Sumathi, V. P., & Grimer, R. J. (2016) · The Bone & Joint Journal · doi:10.1302/0301-620x.98b4.36583 · Cited by 158
Laverdiere, C., Hoang, B. H., Yang, R., Sowers, R., Qin, J., Meyers, P. A., Huvos, A. G., Healey, J. H., & Gorlick, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1089 · Cited by 157 · cited 3×
“linking molecular factors with speciWc disease events include; the association of CXCR4 with micrometastases at diagnosis (Laverdiere et al. 2005), and the association of P-gp with resistance to doxorubicin (Baldini et al.”
BackgroundInactivation of p53 gene in human and murine osteosarcoma cells
Chandar, N., Billig, B., McMaster, J. H., & Novak, J. F. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.43 · Cited by 157 · cited 1×
“In many osteosarcoma cell lines, it is noted that rearrangement of the Wrst intron of the p53 gene occurs consistently, and leads to altered protein expression (Chandar et al. 1992).”
BackgroundResection of recurrent pulmonary metastases in patients with osteosarcoma
Briccoli, A., Rocca, M., Salone, M., Bacci, G., Ferrari, S., Balladelli, A., & Mercuri, M. (2005) · Cancer · doi:10.1002/cncr.21369 · Cited by 151 · cited 4×
“Also in line with this Wnding, another study found that the 5-years survival in those with LR and lung metastases was 6% compared with 37% in patients with only metastases (Briccoli et al. 2005).”
BackgroundMethodResultInfluentialTsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148 · cited 4×
“This trend also correlated with prognosis on Kaplan Meier plots, where down regulation was associated with signiWcantly less survival (Tsukahara et al. 2006).”
BackgroundResultInfluentialLonardo, F., Ueda, T., Huvos, A. G., Healey, J., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8<1541::aid-cncr15>3.0.co;2-y · Cited by 146 · cited 2×
“In terms of inXuencing tumour behaviour, one study examining both p53 mutation and MDM2 expression (a p53 binding/inhibiting protein) in osteosarcoma tissue samples, found no signiWcant relationship between p53 and proliferative rate or histological grade of tumours (Lonardo et al. 1997).”
BackgroundUrokinase Plasminogen Activator System: A Multifunctional Role in Tumor Progression and Metastasis
Choong, P. F. M., & Nadesapillai, A. P. W. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo0000093845.72468.bd · Cited by 145
Self-citationParathyroid Hormone–Related Protein Localization in Breast Cancers Predict Improved Prognosis
Henderson, M. A., Danks, J. A., Slavin, J., Byrnes, G. B., Choong, P., Spillane, J. B., Hopper, J. L., & Martin, T. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2814 · Cited by 143 · cited 1×
“Similarly in a study of PTHrP immunoreactivity in breast cancer and bony metastases, a favourable prognosis was observed in 79% of positive staining tumours over a median 10-years follow-up (Henderson et al. 2006).”
BackgroundSelf-citationKuhn, W. C., Pache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Jänicke, F., & Graeff, H. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1313 · Cited by 138 · cited 2×
“The uPA/uPAR system is upregulated in many common tumours, and speciWcally in colorectal (Ganesh et al. 1994), ovarian (Kuhn et al. 1994), renal (Hofmann et al. 1996) and prostate cancer (McCabe et al. 2000), there is evidence linking an upregulated uPA system with poor survival.”
BackgroundSurvivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond.
Chiou, S., Jones, M. K., & Tarnawski, A. S. (2003) · PubMed · Cited by 137
P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy
Chan, H. S. L., Haddad, G., DeBoer, G., Ling, V. W. T., & Grogan, T. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1706 · Cited by 132 · cited 2×
“levels of expressed P-gp in osteosarcoma is associated with a signiWcant reduction in the probability of remaining event-free after diagnosis but does not correlate with the level of post-chemotherapy tumour necrosis (Baldini et al. 1995; Chan et al. 1997).”
BackgroundPerissinotto, E., Cavalloni, G., Leone, F., Fonsato, V., Mitola, S., Grignani, G., Surrenti, N., Sangiolo, D., Bussolino, F., Piacibello, W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.490.11.2 · Cited by 132
Zhou, H., Randall, R. L., Brothman, A. R., Maxwell, T., Coffin, C. M., & Goldsby, R. E. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200301000-00007 · Cited by 126 · cited 1×
“Conversely, other researchers found positive cytoplasmic staining in 44% of osteosarcoma samples and positivity was correlated with an increased likelihood of metastases and poor outcome (Zhou et al. 2003).”
BackgroundDaw, N. C., Billups, C. A., Galindo, C. R., McCarville, M. B., Rao, B. N., Cain, A. M., Jenkins, J. J., Neel, M. D., & Meyer, W. H. (2005) · Cancer · doi:10.1002/cncr.21626 · Cited by 125 · cited 1×
“This was in contrast to a study by Daw et al. (2006), where there was a survival advantage for patients with no more than three lung nodules, and unilateral lung metastases.”
ResultOsteosarcoma of the Pelvis: Oncologic Results of 40 Patients
Kawai, A., Huvos, A. G., Meyers, P. A., & Healey, J. H. (1998) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199803000-00030 · Cited by 123 · cited 3×
“One study reports an overall 5 years survival of only 34% in patients who had undergone excision and although a wide margin of resection was only achieved in 53% of patients, those who had surgery were still better oV than those treated with non-surgical therapy (Kawai et al. 1998a).”
BackgroundBacci, G., Ferrari, S., Longhi, A., Perin, S., Forni, C., Fabbri, N., Salducca, N., Versari, M., & Smith, K. V. J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00361-0 · Cited by 118 · cited 2×
“Metastases Osteosarcoma metastasises most commonly to the lung (Bacci et al. 2001).”
BackgroundAlteration of pRb/p16/cdk4 regulation in human osteosarcoma
Benassi, M. S., Molendini, L., Gamberi, G., Ragazzini, P., Sollazzo, M. R., Merli, M., Asp, J., Magagnoli, G., Balladelli, A., Bertoni, F., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<489::aid-ijc7>3.0.co;2-d · Cited by 115 · cited 1×
“Similar Wndings have been reported in other studies (Benassi et al. 1999; Feugeas et al. 1996) which are summarised in Table 2.”
ResultBacci, G., Ferrari, S., Longhi, A., Donati, D. M., Manfrini, M., Giacomini, S., Briccoli, A., Forni, C., & Galletti, S. (2003) · Acta Orthopaedica Scandinavica · doi:10.1080/00016470310017776 · Cited by 112 · cited 2×
“In terms of the clinical prognostic factors reviewed, there are clearly a number of discrepancies, but overall the literature supports limb-sparing surgery both in uncomplicated primary disease, and in the setting of pathological fracture (Bacci et al. 2003).”
ResultThe urokinase plasminogen activator receptor as a gene therapy target for cancer
Pillay, V., Dass, C. R., & Choong, P. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.10.011 · Cited by 109 · cited 1×
“Plasmin breaks down extracellular matrix and activates pro-MMPs, which facilitate cancer invasion (Pillay et al. 2007).”
BackgroundSelf-citationPakos, E. E., & Ioannidis, J. P. A. (2003) · Cancer · doi:10.1002/cncr.11546 · Cited by 106 · cited 1×
“Summarising the results of 14 studies on P-gp and clinical outcomes is a meta-analysis, which also conWrms a correlation between positive immunohistochemistry for P-gp and progression of osteosarcoma (Pakos and Ioannidis 2003).”
Takenaka, K., Ishikawa, S., Kawano, Y., Yanagihara, K., Miyahara, R., Otake, Y., Morioka, Y., Takahashi, C., Noda, M., Wada, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.028 · Cited by 104 · cited 1×
“RECK is down regulated in many common tumours including breast (Span et al. 2003), colorectal (van der Jagt et al. 2006), and lung cancer (Takenaka et al. 2004).”
BackgroundTHE SURGICAL TREATMENT AND OUTCOME OF PATHOLOGICAL FRACTURES IN LOCALISED OSTEOSARCOMA
Abudu, A., Sferopoulos, N. K., Tillman, R. M., Carter, S. R., & Grimer, R. J. (1996) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.78b5.0780694 · Cited by 102 · cited 2×
“Similarly, other results (Abudu et al. 1996; Scully et al. 2002) revealed no signiWcant diVerence in survival between the two options, although Abudu et al. found that a signiWcant increase in local recurrence occurred in the instance of limb sparing surgery.”
ResultTakenaka, K., Yamagishi, S., Jinnouchi, Y., Nakamura, K., Matsui, T., & Imaizumi, T. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.048 · Cited by 100 · cited 2×
“It is a signiWcant inhibitor of angiogenesis in osteosarcoma (Ek et al. 2007a) via inhibition of VEGF and induced apoptosis of endothelial cells (Takenaka et al. 2005).”
BackgroundSpan, P. N., Sweep, C. G. J. (., Manders, P., Beex, L. V. A. M., Leppert, D., & Lindberg, R. L. P. (2003) · Cancer · doi:10.1002/cncr.11395 · Cited by 98 · cited 2×
“RECK is down regulated in many common tumours including breast (Span et al. 2003), colorectal (van der Jagt et al. 2006), and lung cancer (Takenaka et al. 2004).”
BackgroundThe Incidence and Prognosis of Osteosarcoma Skip Metastases
Sajadi, K. R., Heck, R. K., Neel, M. D., Rao, B. N., Daw, N. C., Galindo, C. R., Hoffer, F. A., Stacy, G. S., Peabody, T. D., & Simon, M. A. (2004) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000141493.52166.69 · Cited by 97 · cited 3×
“Sajadi et al. (2004) rightly point out that this does not Wt with the current AJCC staging system whereby the presence of lung metastases classiWes the patient as stage IV, versus skip lesions without lung metastases which classiWes the patient in stage III even though this carries a signiWcantly…”
BackgroundInfluentialPrognostic Relevance of Increased Angiogenesis in Osteosarcoma
Kreuter, M., Bieker, R., Bielack, S., Auras, T., Buerger, H., Gosheger, G., Jürgens, H., Berdel, W. E., & Mesters, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0969 · Cited by 90
Stempak, D., Gammon, J., Halton, J., et al. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000243657.64056.c3 · Cited by 88 · cited 1×
“There are studies already in progress examining the combination of low-dose chemotherapy with celecoxib (a known anti-angiogenic angent) (Stempak et al. 2006).”
BackgroundEk, E. T., Dass, C. R., Contreras, K. G., & Choong, P. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701044 · Cited by 87 · cited 2×
“It is a signiWcant inhibitor of angiogenesis in osteosarcoma (Ek et al. 2007a) via inhibition of VEGF and induced apoptosis of endothelial cells (Takenaka et al. 2005).”
BackgroundSelf-citationHofmann, R. W., Lehmer, A., Buresch, M., Härtung, R., & Ulm, K. (1996) · Cancer · Cited by 87 · cited 2×
“1994), renal (Hofmann et al. 1996) and prostate cancer (McCabe et al.”
BackgroundFerrari, S., Bertoni, F., Zanella, L., Setola, E., Bacchini, P., Alberghini, M., Versari, M., & Bacci, G. (2004) · Cancer · doi:10.1002/cncr.20151 · Cited by 81
Franchi, A., Calzolari, A., & Zampi, G. (1998) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050199 · Cited by 75 · cited 2×
“In osteosarcoma elevated c-Fos levels correspond with higher grades of tumour (Franchi et al. 1998; Wu et al. 1990) and also the propensity to develop”
BackgroundEk, E. T., Dass, C. R., Contreras, K. G., & Choong, P. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9062-1 · Cited by 75 · cited 2×
“It is a signiWcant inhibitor of angiogenesis in osteosarcoma (Ek et al. 2007a) via inhibition of VEGF and induced apoptosis of endothelial cells (Takenaka et al. 2005).”
BackgroundSelf-citationPigment epithelium-derived factor: a multimodal tumor inhibitor
Ek, E. T. H., Dass, C. R., & Choong, P. F. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0107 · Cited by 72 · cited 3×
“PEDF is found to be down regulated in many common cancers (Ek et al. 2006a).”
BackgroundResultSelf-citationPark, Y. B., Kim, H. S., Oh, J. H., & Lee, S. H. (2001) · International Orthopaedics · doi:10.1007/s002640000196 · Cited by 69 · cited 4×
“Other researchers (Park et al. 2001) correlated the co-”
BackgroundInfluentialExcision of pulmonary metastases of osteogenic sarcoma of the limbs
Antunes, M., Bernardo, J., Salete, M., Prieto, D., Eugénio, L., & Tavares, P. (1999) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(99)00098-6 · Cited by 68 · cited 1×
“Antunes et al. (1999) found that in pulmonary metastectomies, all patients requiring more than one operation had less than 80% necrosis post chemotherapy.”
BackgroundEndostatin therapy reveals a U-shaped curve for antitumor activity
Sjin, R. M. T. T., Naspinski, J., Birsner, A. E., Li, C., Chan, R., Lo, K.-M., Gillies, S. D., Zurakowski, D., Folkman, J., Samulski, J. R., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700938 · Cited by 68 · cited 1×
“There is a concerted eVort to utilise anti- angiogenic agents, such as Avastin and Endostatin, which work to inhibit the VEGF signalling pathway (Folkman 2004; Tjin Tham Sjin et al. 2006).”
MethodP‐glycoprotein expression in osteosarcoma: A basis for risk‐adapted adjuvant chemotherapy
Baldini, N., Scotlandi, K., Serra, M., Picci, P., Bacci, G., Sottili, S., & Campanacci, M. (1999) · Journal of Orthopaedic Research® · doi:10.1002/jor.1100170502 · Cited by 65 · cited 3×
“2005), and the association of P-gp with resistance to doxorubicin (Baldini et al. 1999).”
Backgroundvan der Jagt, M. F. P., Sweep, F. C. G. J., Waas, E. T., Hendriks, T., Ruers, T. J. M., Merry, A. H. H., Wobbes, T., & Span, P. N. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.06.009 · Cited by 64 · cited 1×
“RECK is down regulated in many common tumours including breast (Span et al. 2003), colorectal (van der Jagt et al. 2006), and lung cancer (Takenaka et al. 2004).”
BackgroundSurvivin as a Prognostic Factor for Osteosarcoma Patients
Osaka, E., Suzuki, T., Osaka, S., Yoshida, Y., Sugita, H., Asami, S., Tabata, K., Hemmi, A., Sugitani, M., Nemoto, N., et al. (2006) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.06005 · Cited by 63 · cited 1×
“Survivin was recently studied in osteosarcoma using RT-PCR for survivin mRNA after extracting RNA from paraYn-embedded osteosarcoma samples (Osaka et al. 2006).”
BackgroundPrognosis of Osteosarcoma With Pulmonary Metastases at Initial Presentation Is Not Dismal
YONEMOTO, T., Tatezaki, S., Ishii, T., Satoh, T., Kimura, H., & Iwai, N. (1998) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199804000-00024 · Cited by 61 · cited 5×
“metastases at diagnosis, the current 5-years survival may be as high as 68% (Yonemoto et al. 1998).”
BackgroundMethodInfluentialUrokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas
Choong, P., Fernö, M., Åkerman, M., Willén, H., Långström, E., Gustaeson, P., Alvegård, T. A., & Rydholm, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960822)69:4<268::aid-ijc5>3.0.co;2-v · Cited by 60
Self-citationManagement and outcome after local recurrence of osteosarcoma
Grimer, R. J., Sommerville, S. M. M., Warnock, D., Carter, S., Tillman, R. M., Abudu, A., & Spooner, D. A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.11.012 · Cited by 56 · cited 1×
“Grimer et al. (2005) found that in cases of LR the only signiWcant prognostic determinant was the presence of concomitant metastases.”
BackgroundYang, R., Hoang, B. H., Kubo, T., Kawano, H., Chou, A. J., Sowers, R. S., Huvos, A. G., Meyers, P. A., Healey, J. H., & Gorlick, R. G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22749 · Cited by 56 · cited 1×
“When PTHR1 was ovexpressed in the HOS osteosarcoma cell line by transfection, increased proliferation, motility and invasion through Matrigel was observed suggesting a tumorigenic role (Yang et al. 2007).”
Kang, H.-G., Kim, H., Kim, K., Oh, J. H., Lee, M., Seol, S. M., & Han, I. (2007) · Journal of Orthopaedic Research® · doi:10.1002/jor.20323 · Cited by 56 · cited 3×
“…glucosamine, histone deacetylases (Vinodhkumar et al. 2007), nitric oxide (Shin et al. 2007), and reversioninducing cysteine-rich protein with Kazal motifs (RECK) (Kang et al. 2007), with an end result in the lab of reduced invasion and metastasis in cultured cells and animal cancer models.”
BackgroundInfluentialDownregulation of uPAR confirms link in growth and metastasis of osteosarcoma
Dass, C. R., Nadesapillai, A. P. W., Robin, D., Howard, M. L., Fisher, J., Zhou, H., & Choong, P. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9004-3 · Cited by 55 · cited 1×
“Down regulating uPAR using antisense clones within an in vivo osteosarcoma model results in reduced primary growth in the tibiae, and inhibition of pulmonary metastases (Dass et al. 2005).”
BackgroundSelf-citationNathan, S. S., Gorlick, R. G., Bukata, S. V., Chou, A. J., Morris, C. D., Boland, P. J., Huvos, A. G., Meyers, P. A., & Healey, J. H. (2006) · Cancer · doi:10.1002/cncr.22197 · Cited by 55 · cited 2×
“Another diVerent perspective is seen in Nathan et al. (2006) where the strongest correlation with poor prognosis was LR within the Wrst year after resection.”
BackgroundInfluentialDutour, A., Monteil, J., Paraf, F., Charissoux, J. L., Kaletta, C., Sauer, B., Naujoks, K., & Rigaud, M. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.008 · Cited by 54 · cited 3×
“Other results (Dutour et al. 2005) suggest that antiangiogenic therapy may still be a very promising therapy in osteosarcoma, however the most appropriate clinical context is yet to be determined.”
BackgroundInfluentialEzrin in osteosarcoma: Comparison between conventional high-grade and central low-grade osteosarcoma
Park, H., Jung, W. W., Bacchini, P., Bertoni, F., Kim, Y.-W., & Park, Y.-K. (2006) · Pathology - Research and Practice · doi:10.1016/j.prp.2006.01.015 · Cited by 52 · cited 1×
“Park et al. (2006) found a correlation between the presence of ezrin and high-grade osteosarcoma, where 43.7% of these were positive but no low-grade osteosarcomas were positive for ezrin.”
BackgroundInfluentialSomers, G. R., Ho, M., Zieleńska, M., Squire, J. A., & Thorner, P. S. (2005) · Pediatric and Developmental Pathology · doi:10.1007/s10024-005-0044-5 · Cited by 50 · cited 1×
“Another study, in this case using immunohistochemistry to analyse HER2 in 34 samples of paediatric osteosarcoma, observed predominantly weak staining (Somers et al. 2005).”
BackgroundMcCabe, N. P., Angwafo, F., Zaher, A., Selman, S. H., Kouinche, A., & Jankun, J. (2000) · Oncology Reports · doi:10.3892/or.7.4.879 · Cited by 46 · cited 2×
“The uPA/uPAR system is upregulated in many common tumours, and speciWcally in colorectal (Ganesh et al. 1994), ovarian (Kuhn et al. 1994), renal (Hofmann et al. 1996) and prostate cancer (McCabe et al. 2000), there is evidence linking an upregulated uPA system with poor survival.”
BackgroundOsteosarcoma of the Hand and Forearm: Experience of the Cooperative Osteosarcoma Study Group
Daecke, W., Bielack, S., Martini, A.-K., Ewerbeck, V., Jürgens, H., Kotz, R. I., Winkelmann, W., Kabisch, H., Kevric, M., & Bernd, L. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.06.002 · Cited by 45 · cited 1×
“One of the highest osteosarcoma survival rates to date has been identiWed in a study on osteosarcomas of the forearm and hand (Daecke et al. 2005).”
BackgroundThe Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations
Lin, A., & Rugo, H. S. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0008-2 · Cited by 39 · cited 2×
“Furthermore, drugs blocking ErbB-2 like herceptin, used successfully in breast cancer clinically (Lin and Rugo 2007) and other cancers in vitro (Saeki et al. 2007), may be beneWcial if patients with osteosarcoma were found to over express ErbB-2.”
BackgroundMethodPrimary Osteosarcoma in Patients Older than 40 Years of Age
Jeon, D. G., Lee, S. Y., Cho, W. H., Song, W. S., & Park, J. H. (2006) · Journal of Korean Medical Science · doi:10.3346/jkms.2006.21.4.715 · Cited by 39 · cited 1×
“A higher rate of axial tumours has been reported in those over 40 years (Bielack et al. 2002), and a further study identiWed an axial site of presentation in 20.5% of those greater than 40 years compared with 4.7% in adolescent patients with a P-value of 0.035 (Jeon et al. 2006).”
BackgroundInfluentialVinodhkumar, R., Song, Y., Ravikumar, V., Ramakrishnan, G., & Devaki, T. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.012 · Cited by 39 · cited 1×
“MMP-9 is already known to be inhibited by a number of substances including sulfated glucosamine, histone deacetylases (Vinodhkumar et al. 2007), nitric oxide (Shin et al. 2007), and reversioninducing cysteine-rich protein with Kazal motifs (RECK) (Kang et al. 2007), with an end result in the lab of…”
BackgroundEk, E. T., Ojaimi, J., Kitagawa, Y., & Choong, P. (2006) · Oncology Reports · doi:10.3892/or.16.1.17 · Cited by 38 · cited 3×
“PEDF is found to be down regulated in many common cancers (Ek et al. 2006a).”
BackgroundResultSelf-citationKido, A., Tsutsumi, M., Iki, K., Takahama, M., Tsujiuchi, T., Morishita, T., Tamai, S., & Konishi, Y. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00368-1 · Cited by 36 · cited 3×
“The importance of MMP-9 in osteosarcoma was also demonstrated by Kido et al. (1999) who showed that over expression of this enzyme in rat osteosarcoma was associated with increased metastatic potential.”
BackgroundHeinsohn, S., Evermann, U., Stadt, U. Z., Bielack, S., & Kabisch, H. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.5.1205 · Cited by 35 · cited 1×
“Heinsohn et al. (2007) found Rb LOH in 39% of 41 osteosarcoma patients but there was no correlation with overall survival or eventfree survival in these patients.”
BackgroundMechtersheimer, G., Staudter, M., Majdic, O., Dörken, B., Moldenhauer, G., & Möller, P. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460512 · Cited by 34 · cited 1×
“Mechtersheimer et al. (1990) also studied HLA-I expression and found no down regulation, although sample size was very small at four.”
BackgroundShin, C. Y., Lee, W. J., Choi, J. W., Choi, M. S., Ryu, J. R., Oh, S. J., Cheong, J. H., Choi, E. Y., & Ko, K. H. (2007) · Nitric Oxide · doi:10.1016/j.niox.2007.03.004 · Cited by 31 · cited 2×
“2007), nitric oxide (Shin et al. 2007), and reversioninducing cysteine-rich protein with Kazal motifs (RECK) (Kang et al.”
BackgroundManagement of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience
Aksnes, L. H., Hall, K. S., Follerås, G., Stenwig, A. E., Bjerkehagen, B., Taksdal, I., Winderen, M., Bruland, Ø. S., & Sæter, G. (2006) · Acta Oncologica · doi:10.1080/02841860500466624 · Cited by 31 · cited 3×
“…absolute tumour volume, stage and site of the tumour remain the most useful because in general they have clear cut-oV points identiWed in the literature between good and bad outcomes, for example age greater than 40 (Aksnes et al. 2006), and tumour volume greater than 150 cm3 (Bieling et al. 1996).”
BackgroundUse of chemotherapy for retinoblastoma
Pratt, C. B. (1998) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199812)31:6<471::aid-mpo2>3.0.co;2-m · Cited by 10 · cited 1×
“For example, Himelstein et al. (1998) showed positive staining in all paediatric osteosarcomas studied.”
Background
Cited by
Osteosarcoma treatment – Where do we stand? A state of the art review
Luetke, A., Meyers, P. A., Lewis, I., & Juergens, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.006 · Cited by 1,234
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 689
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Self-citationRb regulates fate choice and lineage commitment in vivo
Calo, E., Quintero-Estades, J. A., Danielian, P. S., Nedelcu, S., Berman, S. D., & Lees, J. A. (2010) · Nature · doi:10.1038/nature09264 · Cited by 314
Dong, Y., Liang, G., Yuan, B., Yang, C., Gao, R., & Zhou, X. (2015) · Tumor Biology · doi:10.1007/s13277-014-2631-4 · Cited by 313
Metadata
- Authors
- Clark, J. C. M., Dass, C. R., & Choong, P. F. M.
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2007-10-27
- Volume
- 134
- Issue
- 3
- Pages
- 281-297
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- OpenAlex
- W2018441425
- Cited by
- 250
- References
- 112
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.